Literature DB >> 19454671

IL-15 renders conventional lymphocytes resistant to suppressive functions of regulatory T cells through activation of the phosphatidylinositol 3-kinase pathway.

Mélika Ben Ahmed1, Nadia Belhadj Hmida, Nicolette Moes, Sophie Buyse, Maha Abdeladhim, Hechmi Louzir, Nadine Cerf-Bensussan.   

Abstract

IL-15 drives chronic inflammation in several human diseases. We have recently shown that IL-15 inhibits the immunosuppressive effects of TGF-beta through blockage of the Smad3-signaling pathway. Data pointing to reciprocal interactions between TGF-beta and CD4(+) regulatory T cells led us to investigate the impact of IL-15 on the de novo generation and function of regulatory T cells in humans. Our data indicate that IL-15 does not counteract, but rather promotes the effect of TGF-beta on the de novo generation of regulatory T cells (Treg). Thus, in the presence of TGF-beta, IL-15 enhanced the acquisition of regulatory functions by CD4(+)CD25(-) T cells stimulated by anti-CD3 and anti-CD28 Abs. In contrast, IL-15 impaired the functions of Tregs by acting on effector CD4 and CD8 T cells. Accordingly, in the presence of IL-15, proliferation and IFN-gamma production by peripheral CD4 and CD8 T cells could not be efficiently inhibited by Tregs. IL-15-induced resistance of effector T cells to Tregs resulted from activation of the PI3K signaling pathway but did not involve the rescue of effector T cells from apoptosis. Altogether, these data point to the ambiguous role of IL-15 in the control of Treg functions. This dual role may be instrumental to mount rapid but transient proinflammatory immune responses against pathogens but may become deleterious in situations associated with protracted IL-15 over-expression.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19454671     DOI: 10.4049/jimmunol.0801792

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  52 in total

1.  Cerebral interleukin-15 shows upregulation and beneficial effects in experimental autoimmune encephalomyelitis.

Authors:  Xiaojun Wu; Weihong Pan; Yi He; Hung Hsuchou; Abba J Kastin
Journal:  J Neuroimmunol       Date:  2010-04-28       Impact factor: 3.478

Review 2.  Combination strategies to enhance antitumor ADCC.

Authors:  Holbrook E Kohrt; Roch Houot; Aurélien Marabelle; Hearn Jay Cho; Keren Osman; Matthew Goldstein; Ronald Levy; Joshua Brody
Journal:  Immunotherapy       Date:  2012-05       Impact factor: 4.196

Review 3.  The role of interleukin-15 in inflammation and immune responses to infection: implications for its therapeutic use.

Authors:  Pin-Yu Perera; Jack H Lichy; Thomas A Waldmann; Liyanage P Perera
Journal:  Microbes Infect       Date:  2011-10-25       Impact factor: 2.700

4.  Interleukin-15 enhances T-cell responses by stimulation with dendritic cells.

Authors:  Yu Zhao; Ke Cheng; Yang Wu; Xing-Chen Peng; Ye Chen; Ben-Xu Tan; Jun Ge; Hang Dong; Meng Wei; Feng Gao; Jing-Mei Su; Jian-Mei Hou; Ji-Yan Liu
Journal:  Clin Transl Oncol       Date:  2011-04       Impact factor: 3.405

Review 5.  Tissue-mediated control of immunopathology in coeliac disease.

Authors:  Bana Jabri; Ludvig M Sollid
Journal:  Nat Rev Immunol       Date:  2009-12       Impact factor: 53.106

Review 6.  Effector and suppressor T cells in celiac disease.

Authors:  Giuseppe Mazzarella
Journal:  World J Gastroenterol       Date:  2015-06-28       Impact factor: 5.742

Review 7.  Innate immunity: actuating the gears of celiac disease pathogenesis.

Authors:  Sangman Michael Kim; Toufic Mayassi; Bana Jabri
Journal:  Best Pract Res Clin Gastroenterol       Date:  2015-05-11       Impact factor: 3.043

8.  Interleukin 15 provides relief to CTLs from regulatory T cell-mediated inhibition: implications for adoptive T cell-based therapies for lymphoma.

Authors:  Serena K Perna; Biagio De Angelis; Daria Pagliara; Sayyeda T Hasan; Lan Zhang; Aruna Mahendravada; Helen E Heslop; Malcolm K Brenner; Cliona M Rooney; Gianpietro Dotti; Barbara Savoldo
Journal:  Clin Cancer Res       Date:  2012-11-13       Impact factor: 12.531

9.  Signaling through the adaptor molecule MyD88 in CD4+ T cells is required to overcome suppression by regulatory T cells.

Authors:  Dominik Schenten; Simone A Nish; Shuang Yu; Xiting Yan; Heung Kyu Lee; Igor Brodsky; Lesley Pasman; Brian Yordy; F Thomas Wunderlich; Jens C Brüning; Hongyu Zhao; Ruslan Medzhitov
Journal:  Immunity       Date:  2014-01-16       Impact factor: 31.745

10.  Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety.

Authors:  V Hoyos; B Savoldo; C Quintarelli; A Mahendravada; M Zhang; J Vera; H E Heslop; C M Rooney; M K Brenner; G Dotti
Journal:  Leukemia       Date:  2010-04-29       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.